tetano
Editor, Senior Moderator
J Infect Dis. 2020 Feb 26. pii: jiaa080. doi: 10.1093/infdis/jiaa080. [Epub ahead of print] Relative effectiveness of influenza vaccines among the U.S. elderly, 2018-19.
Izurieta HS[SUP]1[/SUP], Chillarige Y[SUP]2[/SUP], Kelman J[SUP]3[/SUP], Wei Y[SUP]2[/SUP], Lu Y[SUP]1[/SUP], Xu W[SUP]2[/SUP], Lu M[SUP]2[/SUP], Pratt D[SUP]1[/SUP], Wernecke M[SUP]2[/SUP], MaCurdy T[SUP]2,[/SUP][SUP]4[/SUP], Forshee R[SUP]1[/SUP].
Author information
Abstract
BACKGROUND:
Studies among individuals ages ≥65 years have found a moderately higher relative vaccine effectiveness (RVE) for the high-dose (HD) influenza vaccine compared to standard-dose (SD) products for most seasons. Studies during the A(H3N2)-dominated 2017-18 season showed slightly higher RVE for the cell-cultured vaccine compared to SD egg-based vaccines. We investigated the RVE of influenza vaccines among Medicare beneficiaries ages ≥65 years during the 2018-19 season.
METHODS:
Retrospective cohort study using inverse probability of treatment weighting and Poisson regression to evaluate RVE in preventing influenza hospital encounters.
RESULTS:
Among 12,777,214 beneficiaries, the egg-based adjuvanted (RVE 7.7%, 95% CI: 3.9 to 11.4%) and high-dose (RVE 4.9%, 95% CI: 1.7 to 8.1%) vaccines were marginally more effective than the egg-based quadrivalent vaccines. The cell-cultured quadrivalent vaccines were not significantly more effective than the egg-based quadrivalent vaccines (RVE 2.5%, 95% CI: -2.4 to 7.3%).
CONCLUSIONS:
We did not find major effectiveness differences between licensed vaccines used among the elderly during the 2018-19 season. Consistent with prior research, we found that the egg-based adjuvanted and high-dose vaccines were slightly more effective than the egg-based quadrivalent vaccines.
Published by Oxford University Press for the Infectious Diseases Society of America 2020. This work is written by (a) US Government employee(s) and is in the public domain in the US.
KEYWORDS:
Influenza vaccine; adjuvanted vaccine; cell-cultured vaccine; high-dose vaccine; relative effectiveness; vaccine effectiveness
PMID: 32100009 DOI: 10.1093/infdis/jiaa080
Izurieta HS[SUP]1[/SUP], Chillarige Y[SUP]2[/SUP], Kelman J[SUP]3[/SUP], Wei Y[SUP]2[/SUP], Lu Y[SUP]1[/SUP], Xu W[SUP]2[/SUP], Lu M[SUP]2[/SUP], Pratt D[SUP]1[/SUP], Wernecke M[SUP]2[/SUP], MaCurdy T[SUP]2,[/SUP][SUP]4[/SUP], Forshee R[SUP]1[/SUP].
Author information
Abstract
BACKGROUND:
Studies among individuals ages ≥65 years have found a moderately higher relative vaccine effectiveness (RVE) for the high-dose (HD) influenza vaccine compared to standard-dose (SD) products for most seasons. Studies during the A(H3N2)-dominated 2017-18 season showed slightly higher RVE for the cell-cultured vaccine compared to SD egg-based vaccines. We investigated the RVE of influenza vaccines among Medicare beneficiaries ages ≥65 years during the 2018-19 season.
METHODS:
Retrospective cohort study using inverse probability of treatment weighting and Poisson regression to evaluate RVE in preventing influenza hospital encounters.
RESULTS:
Among 12,777,214 beneficiaries, the egg-based adjuvanted (RVE 7.7%, 95% CI: 3.9 to 11.4%) and high-dose (RVE 4.9%, 95% CI: 1.7 to 8.1%) vaccines were marginally more effective than the egg-based quadrivalent vaccines. The cell-cultured quadrivalent vaccines were not significantly more effective than the egg-based quadrivalent vaccines (RVE 2.5%, 95% CI: -2.4 to 7.3%).
CONCLUSIONS:
We did not find major effectiveness differences between licensed vaccines used among the elderly during the 2018-19 season. Consistent with prior research, we found that the egg-based adjuvanted and high-dose vaccines were slightly more effective than the egg-based quadrivalent vaccines.
Published by Oxford University Press for the Infectious Diseases Society of America 2020. This work is written by (a) US Government employee(s) and is in the public domain in the US.
KEYWORDS:
Influenza vaccine; adjuvanted vaccine; cell-cultured vaccine; high-dose vaccine; relative effectiveness; vaccine effectiveness
PMID: 32100009 DOI: 10.1093/infdis/jiaa080